If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

Dr Louise Mackenzie is an in vitro pharmacologist who works on numerous projects involved with molecular mechanisms that underpin numerous disease states, such as nuclear receptors involved in inflammation.

Her background has been to study vasoactive compounds that control vascular function, but more recently she has worked in multi-disciplinary groups to screen for drugs that control pancreatic diseases, both diabetes and cancer.

Supervisory Interests

Nuclear receptors control transcription and therefore they control how cells differntiate and function. Projects involve changing cell function in a variety of ways, for example manipulating human blood derived progenitor cells to create new organs such as lung and deepening our understanding of how PPARβδ receptors control inflammation and disease. As a pharmacologist I also have a greta deal of interest in defining the link between NSAIDs and cardiovascular diseases, and currently reseach off-target effects of these important drugs.

Two other in vitro projects in collaboration with other universities; to isolate or identify hit compounds to control diabetes and pancreatic cancer. One set of compounds have been isolated form natural plant products from Gabon (the extract is already in use to control diabetes in humans), while the other screening cascade involves compounds have been designed via computitonal chemsitry Collaborators: Hertfordshire University and IPHAMETRA institute, Gabon.

Education/Academic qualification

University of Hertfordshire

PhD, Imperial College London

1 Oct 20001 Oct 2003

Bachelor, University of Warwick

Fingerprint Dive into the research topics where Louise MacKenzie is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 1 Similar Profiles
Celecoxib Medicine & Life Sciences
Blood Vessels Medicine & Life Sciences
Cyclooxygenase 2 Medicine & Life Sciences
Peroxisome Proliferator-Activated Receptors Medicine & Life Sciences
Epoprostenol Medicine & Life Sciences
Endothelium Medicine & Life Sciences
Cyclooxygenase 1 Medicine & Life Sciences
Vasodilation Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1998 2019

Off-target interactions as novel explantion of NSAID CV risk

Dolan, G., MacKenzie, L., Zloh, M. & Lione, L., Apr 2019.

Research output: Contribution to conferenceAbstract

Open Access
File
Cardiovascular Agents
Anti-Inflammatory Agents
Diclofenac
Naproxen
Cytoplasmic and Nuclear Receptors

Regulation of pulmonary artery inflamation by PPARβ/δ

Perez Diaz, N., Lione, L., MacKenzie, L. & Hutter, V., Apr 2019.

Research output: Contribution to conferenceAbstract

Open Access
File
PPAR delta
Pulmonary Artery
Inflammation
Transcription Factors
Anti-Inflammatory Agents

An overview of anti-diabetic plants used in Gabon: Pharmacology and toxicology

Bading Taika, B., Bouckandou, M., Souza, A., Bourobou Bourobou, H. P., Mackenzie, L. & Lione, L. A., 2 Jan 2018, In : Journal of Ethnopharmacology. 216, p. 203-228 26 p.

Research output: Contribution to journalArticle

Open Access
File
Gabon
Toxicology
Pharmacology
Hyperglycemia
Tabernaemontana

Predicted interactions of selected NSAIDS with hERG potassium channel using Virtual Toxlab

Dolan, G., MacKenzie, L., Zloh, M. & Lione, L., Mar 2018.

Research output: Contribution to conferenceAbstract

Open Access
File
Celecoxib
Potassium Channels
Anti-Inflammatory Agents
Cardiac Arrhythmias
etoricoxib

The non-genomic effects of the PPARβ/δ agonist GW0742 on STZ treated rat aorta

Perez-Diaz, N., Pushkarsky, I., Oweis, N., Lione, L. A. & Mackenzie, L., 31 Dec 2018, In : Current Molecular Pharmacology. 11, 2, p. 149-154 6 p.

Research output: Contribution to journalArticle

Peroxisome Proliferator-Activated Receptors
Aorta
Dilatation
GW0742
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid